Double-Stent System with Long Duodenal Extension for Palliative Treatment of Malignant Extrahepatic Biliary Obstructions: A Prospective Study

Dong Il Gwon, MD, Gi-Young Ko, MD, Jong Woo Kim, MD, Heung Kyu Ko, MD, Hyun-Ki Yoon, MD, Kyu-Bo Sung, MD

All authors: Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Korea

Objective: To investigate the technical safety and clinical efficacy of a double-stent system with long duodenal extension in patients with malignant extrahepatic biliary obstruction.

Materials and Methods: This prospective study enrolled 48 consecutive patients (31 men, 17 women; mean age, 61 years; age range, 31–77 years) with malignant extrahepatic biliary obstructions from May 2013 to December 2015. All patients were treated with a double-stent system with long duodenal covered extension (16 cm or 21 cm).

Results: The stents were successfully placed in all 48 patients. There were five (10.4%) procedure-related complications. Minor complications were self-limiting hemobilia (n = 2). Major complications included acute pancreatitis (n = 1) and acute cholecystitis (n = 2). Successful internal drainage was achieved in 42 (87.5%) patients. Median patient survival and stent patency times were 92 days (95% confidence interval [CI], 61–123 days) and 83 days (95% CI, 46–120 days), respectively. Ten (23.8%) of the 42 patients presented with stent occlusion due to food impaction with biliary sludge, and required repeat intervention. Stent occlusion was more frequent in metastatic gastric cancer patients with pervious gastrectomy, but did not reach statistical significance (p = 0.069).

Conclusion: Percutaneous placement of a double-stent system with long duodenal extension is feasible and safe. However, this stent system does not completely prevent stent occlusion caused by food reflux.

Keywords: Biliary; Malignancy; Obstruction; Stent

INTRODUCTION

Insertion of self-expanding metallic stents has become an established method of palliative treatment to relieve malignant biliary obstructions (1-4). The use of covered stents in the biliary system was initially developed to address the issue of tumor ingrowth. A variety of covering materials have been manufactured and tested to prevent tumor ingrowth and to avoid the need for re-intervention (5-15). In last 12 years, polytetrafluoroethylene (PTFE)-covered stents have been demonstrated as an effective treatment method (9-15), with the PTFE material serving as an effective barrier to prevent tumor ingrowth.

Although PTFE-covered stents can prevent tumor ingrowth and are associated with relatively low rates of stent occlusion (9-15), stent dysfunction induced by the food impaction and the deposition of biliary sludge composed of cholesterol crystals, calcium bilirubinate and palmitate, cholesterol, bacteria and/or fungi, microbial byproducts, proteins, dietary fibers, and glycoproteins is a major cause...
of stent dysfunction, especially when stents are placed across the ampulla of Vater (15-18).

A prospective multicenter study of 160 patients, introduced the efficacy of the double stent system (15). While the results of that study were promising, further reduction of the incidence of sludge incrustation was warranted. As duodenobiliary reflux and subsequent biofilm formation in a stent lumen may be important in initiating sludge formation and subsequent stent occlusion (18-23), there is a need for antireflux stents that prevent covered stent dysfunction resulting from duodenobiliary reflux.

With this goal, we modified an inner covered stent of the double stent system to reduce duodenobiliary reflux. Our hypothesis was that a long inner covered stent placed in the distal duodenum or proximal jejunum will reduce reflux into biliary system. The purpose of our study was to investigate the safety and efficacy of a double-stent system with long duodenal covered extension in patients with malignant extrahepatic biliary obstruction.

**MATERIALS AND METHODS**

**Patients**

This was a prospective single center study that enrolled 48 consecutive patients (31 men, 17 women; mean age, 61 years; range, 31−77 years) with malignant extrahepatic biliary obstructions from May 2013 to December 2015. The study was approved by the Institutional Review Board of our Institution and informed consent was obtained from each patient. Patients were included if they had an extrahepatic biliary obstruction caused by a malignancy that could not be treated surgically, due to unresectability, late tumor stage, advanced age, or a comorbid condition; if an endoscopic attempt to drain the obstructed bile ducts was unsuccessful; and if they had recurrent endoscopic stent dysfunction caused by food impaction. Exclusion criteria included abnormal coagulation status (international normalized ratio ≥ 1.5 and platelet count ≤ 50000/mm³), and poor general health status (Eastern Cooperative Oncology Group performance status grade 4).

**Device**

The double-stent system (GD Stent; TaeWoong Medical, Gimpo, Korea) (Fig. 1) is composed of two stents. The outer, self-expanding, uncovered stent (Niti-D stent) consisted of a double 0.007-inch-diameter nitinol wire in a tubular configuration, with an interlocking and diamond-shaped pattern. The outer uncovered stent was 10 mm in diameter and 8 cm in length. A 2-cm proximal uncovered metal extension was available for intrahepatic overstenting. The inner, conical-configured covered stent consisted of an outer expanded PTFE membrane and the inner supporting self-expanding uncovered stent (Niti-S stent) consisted of a single 0.006-inch-diameter nitinol wire. The proximal and distal diameters of the inner covered stent were 10 mm and 8 mm, respectively. The length of inner covered stent was 16 mm or 21 cm. Radiopaque gold markers were incorporated into the ends of both the inner and outer stents to increase stent visibility during placement under fluoroscopic guidance, and the two stents were knitted together by nylon sutures. The delivery system was a standard push-rod assembly consisting of a 9 Fr sheath and an inner catheter. Following deployment, these double stents shortened by 20%.

**Technique**

Prior to percutaneous transhepatic biliary drainage (PTBD), computed tomography (CT), magnetic resonance cholangiopancreatography or endoscopic retrograde cholangiopancreatography was performed to assess the anatomy and to plan the most appropriate approach for intervention. PTBD and stent insertion were performed under conscious sedation using intravenous pethidine hydrochloride (Demerol, Keukdong Pharmaceuticals, Seoul, Korea) and local anesthesia using 2% lidocaine (Jeil Pharmaceuticals, Daegu, Korea). Antibiotics were
administered intravenously 2 hours before the procedure and for at least 48 hours afterwards. The intrahepatic bile duct was punctured using a 21-gauge Chiba needle (Cook, Bloomington, IN, USA) under the guidance of fluoroscopy or ultrasonography, and an 8.5 Fr drainage catheter (Cook) was inserted. Using cholangiography, we determined the location and length of the biliary stricture. The endoprosthesis was introduced over a 0.035-inch, 250-cm-long stiff hydrophilic guide wire (Terumo, Tokyo, Japan) or over an extra stiff Amplatz guide wire (Cook), and then deployed across the stricture to cover the bile duct approximately 2 cm proximal to the obstruction to prevent tumor overgrowth. In all patients, the distal portion of the stent was placed across the papilla to bridge the duodenum or jejunum (Fig. 2). Pre- and post-stenting balloon dilation was not performed in any patient.

Prior to catheter removal, the biliary drainage catheter was clamped and left in place for 2–3 days to evaluate stent patency. During that time, patients ate a soft or normal diet. Correct position and function of the stent and food reflux were evaluated by follow-up cholangiography and bile aspiration performed through the catheter after clamp period. The catheter was subsequently removed if free contrast flow through the stent into the duodenum or the jejunum was documented and if serum bilirubin level was markedly decreased or normalized.

Follow-Up

All patients were evaluated clinically at the interventional radiology outpatient clinic, including measurements of their total serum bilirubin levels, 1, 6, and 12 months after their procedures, or if there were unexpected symptoms or signs such as jaundice, pain, or fever. The cutoff date for data analysis was December 31, 2016. Beginning 12 months after stent placement, all patients were interviewed by telephone monthly, until recurrence of obstructive jaundice or death, to evaluate overall stent patency and patient survival. Complications were diagnosed by clinical and laboratory examinations and, when necessary, by imaging modalities. Patients with recurrent jaundice were evaluated by CT or percutaneous transhepatic cholangiography. If stent occlusion was detected, the stent was revised percutaneously by inserting a biliary drainage catheter with/without balloon dilation or metallic stents.

Study Endpoints and Definitions

Major study endpoints were assessment of technical success, complications, successful internal drainage, patient survival, and stent patency. Technical success was defined as placement of the stent in an adequate position without migration. Complications were classified as major and minor according to the guidelines of the Society of Interventional Radiology Standards of Practice Committee (24). Successful internal drainage was defined as a decrease in serum bilirubin level to < 75% of the pretreatment value within the first month following stent placement. Patient survival was defined as the time interval between the initial stent placement and death or last follow-up. Stent patency was defined as the time interval between the initial stent placement and recurrence of the obstruction or death. Stent
occlusion was defined as a radiologically confirmed biliary obstruction with serum bilirubin levels > 3 mm/dL, or as any condition requiring repeat intervention in order to improve the biliary drainage.

**Statistical Analyses**

Paired-sample t test was used to compare the pre- and post-stenting serum bilirubin levels. Stent patency and patient survival rates were calculated according to the Kaplan-Meier method, and differences between curves were analyzed by the log-rank test. All statistical analyses were performed using SPSS version 14.0 (SPSS Inc., Chicago, IL, USA), with p < 0.05 indicating statistical significance.

**RESULTS**

**Patient Characteristics**

Baseline demographic and clinical data are presented in Table 1. A diagnosis of malignant extrahepatic biliary obstruction was confirmed in 21 (43.8%) patients by pathologic examination of endoscopic biopsy (n = 16), percutaneous biopsy (n = 3), and surgical biopsy (n = 2) specimens. In the remaining 27 (56.2%) patients, diagnosis was based on clinical and radiologic findings. Among 23 patients with malignant extrahepatic biliary obstruction caused by metastatic gastric cancer, 18 had undergone gastrectomy comprising total gastrectomy (n = 6), subtotal gastrectomy (n = 3), and distal gastrectomy (n = 9).

**Technical and Clinical Outcomes and Complications**

The technical success rate of the double-stent placement was 100%. The radiopaque markers embedded in the device were visible fluoroscopically and allowed accurate stent placement in satisfactory positions without any complications. A single stent was sufficient to relieve malignant biliary obstruction in all 48 patients. Forty one patients received 10 mm x 23 cm stent and seven received the 10 mm x 18 cm stent. In the seven patients, the primary stenting technique consisted of direct placement of the double stent. In the remaining 41 patients with symptoms or signs of cholangitis, the stent was implanted 4−17 days (mean 5.3 days) after initial drainage (Fig. 3).

Procedure-related minor complication occurred in two patients. They experienced self-limiting hemobilia that completely resolved 1 and 2 days following stent placement and without transfusion. Procedure-related major complication occurred in one patient; acute pancreatitis occurred immediately after stent placement in one patient and was successfully treated by conservative management over 4 days. Late complication in two patients was acute cholecystitis at 131 and 135 days. Both cases were successfully treated by transhepatic gallbladder drainage. Acute cholecystitis was associated with tumor invasion of the cystic duct orifice in these two patients with advanced gastric cancer. Duodenal or jejunal complications related to the dual stent system were not observed during the follow-up period. Therefore, the overall complication rate was 10.4% (five of 48 patients).

Follow-up cholangiography after clamp test period (mean, 2.7 days; range, 2−3 days) showed patent stent in 43 (89.6%) patients and immediate stent dysfunction due to food reflux in three (6.3%). In the remaining two patients, follow-up cholangiography and subsequent removal of their drainage catheters could not be performed due to their early death. The two patients died 6 and 9 days after stent placement due to rapidly progressing underlying malignancy. Among the 43 patients with patent stent, 42 were free of external drainage catheter after follow-up cholangiography. In the remaining one patient with a patent stent, the drainage catheter could not be removed due to progressive increase in serum bilirubin level. Three patients experienced food reflux with stent dysfunction. Their drainage catheters could not be removed due to recurrent food reflux despite frequent irrigation of the bile duct and stent. Successful internal drainage was achieved in 42 (87.5%) of 48 patients.

| Table 1. Patient Characteristics |
|---------------------------------|
| Characteristics                  | Value  |
| Sex                             |        |
| Male                            | 31     |
| Female                          | 17     |
| Mean age (years) (range)        | 61 (31−77) |
| Underlying malignancy           |        |
| Advanced gastric cancer          | 23 (47.9) |
| Pancreatic cancer                | 17 (35.4) |
| Bile duct cancer                 | 3 (6.25) |
| Metastatic cancer                | 2 (4.2) |
| Others*                         | 3 (6.25) |
| Level of obstruction             |        |
| Upper common bile duct          | 16 (33.3) |
| Lower common bile duct          | 19 (39.6) |
| Whole common bile duct          | 13 (27.1) |
| Initial mean serum bilirubin level (mg/dL) | 8.6 |

Except where noted otherwise, data are no. (%) of patients.

* Ampulla of Vater cancer (n = 1), gallbladder cancer (n = 1), and hepatocellular carcinoma (n = 1)
The mean serum bilirubin level which was $8.6 \pm 6.6\, \text{mg/dL}$ before drainage and decreased significantly to $2.6 \pm 3.2\, \text{mg/dL}$ one month after biliary stent insertion ($p < 0.001$).

**Patient Survival**

Clinical follow-up until death or the end of the study was available for all patients and lasted 9−448 days (mean, 105 days). Following stent placement, 47 (97.9%) of 48 patients died, whereas one (2.1%) remained alive. According to the Kaplan-Meier survival analysis, the median survival time was 92 days (95% confidence interval [CI], 61−123 days) (Fig. 4).

**Stent Patency**

Kaplan-Meier analysis revealed a median stent patency time of 83 days (95% CI, 46−120 days) (Fig. 5). Stent occlusion was observed in ten (23.8%) of 42 patients after a mean interval of 130 days (range, 21−400 days). Among the ten patients, six had only jaundice and two had jaundice with cholangitis. The mean serum bilirubin level was $3.7 \pm 2.3\, \text{mg/dL}$ (range, 2.2−8.3 mg/dL). In the remaining two patients, stent dysfunction was suspected on follow-up CT. The ten patients were treated with PTBD. Stent occlusion was caused by food impaction with or without subsequent biliary sludge in all ten. Food materials

---

**Fig. 3.** 64-year-old woman with pancreatic cancer. Patient had dysfunction of endoscopic metallic stent and subsequently inserted plastic stent.

A. Cholangiogram shows multifocal filling defects in bile duct and dysfunction of endoscopic metallic and plastic stent. B. After removal of plastic stent, bile duct and metallic stent were irrigated through drainage catheter. C. Cholangiogram after placement of double stents (10 mm x 23 cm) shows fluent passage of contrast medium through stent into jejunum. Note inner covered stent (arrows) and outer uncovered stent (arrowheads).

**Fig. 4.** Kaplan-Meier survival curve.

**Fig. 5.** Kaplan-Meier curve showing patency rate of stent system.
and sludge were confined to duodenal extension in seven patients, and food materials and sludge were found in the bile duct as well as duodenal extension in three. None of these patients was managed by insertion of an additional stent due to firmly occluded duodenal extension by food materials and sludge \((n = 2)\) and rapidly progressing disease with poor general condition \((n = 8)\). Log-rank analysis revealed a higher incidence of stent occlusion in metastatic gastric cancer patients with previous gastrectomy, but was not statistically significant \(( \rho = 0.069)\). Tumor ingrowth was not noted in any patient. Therefore, overall stent occlusion after stent placement occurred in 13 \((33.3\%)\) of 39 patients.

**DISCUSSION**

Previous studies reported that duodenobiliary reflux is a major cause of cholangitis and plays an important role in stent dysfunction \((18-23)\). In these studies, patients with biliary metallic stents had episodes of unexplained fever or cholangitis, as seen from 6.5\% to 22\% and metallic stent placement across the main papilla may predispose patients to cholangitis because of disruption of the sphincter mechanism. A previous study using barium examination revealed free barium refluxes through the transpapillary biliary metallic stents in all patients \((25)\). Moreover, the dietary fibers accelerate bacterial attachment, increase the amount of bile sludge formation, and potentially decrease the long-term patency rate of these stents \((16-18)\). A previous study that used confocal laser scanning and scanning electron microscopy described that networks of large dietary fibers covered with microorganisms resulting from duodenal reflux were a major contributing factor in stent occlusion \((18)\). A recent prospective, randomized study in 77 patients with unresectable distal malignant biliary obstruction at a single center using covered stent system with antireflux valve and conventional covered stent reported that significantly longer stent patency rates in the antireflux stent group than in the conventional covered stent group \((23)\). However, this stent system did not completely prevent duodenobiliary reflux on barium meal examination after stent placement. Therefore, a newly designed approach was needed to target the influence of duodenobiliary reflux on stent patency rates.

The present prospective study assessed the PTFE-covered stent system with long duodenal covered extension. The original design of the covered stent system was intended to treat malignant extrahepatic biliary obstruction \((14, 15)\). We modified an inner covered stent to reduce the incidence of stent dysfunction caused by duodenobiliary reflux. In the present study, stent deployment was technically successful in all patients, and correct positioning was verified after all placements. There was no additional difficulty in placing this stent system compared with the conventional metallic stents. The introducer system was 9 Fr in diameter, which is acceptable size because the PTBD catheters used in our institution are of a similar size \((8.5 \text{ Fr})\). The complication rate \((10.4\%)\) and successful internal drainage rate \((87.5\%)\) agreed with the results of previous studies using PTFE-covered stents \((8-14)\). Duodenal or jejunal complications related to the dual stent system were not observed during the follow-up period.

Stent occlusion occurred in 10 \((23.8\%)\) of 42 patients. The cause of stent occlusion was food impaction with/without biliary sludge. In prior studies using PTFE-covered stents, the stent occlusion rates ranged from 9−19\% \((9-15)\). It is difficult to compare our results with the prior findings. However, the stent occlusion rate we observed was similar to those in studies using PTFE-covered stents. Prior to the present study, we anticipated that a long inner PTFE-covered stent placed in the distal duodenum or proximal jejunum would reduce food reflux into biliary system and improve internal bile drainage. Moreover, the inner covered stent has no side holes, thereby avoiding reflux of duodenal contents into the inner stent, bypassing the distal end. However, this stent system did not completely prevent stent occlusion caused by food reflux. Among ten patients who had stent occlusion, food materials and sludge were confined to duodenal extension in seven patients and food materials and sludge were found in the bile duct as well as duodenal extension in three patients. The long duodenal extension could contribute to food stasis in the stent lumen. In addition, although the incidence of stent occlusion did not reach statistical significance, there was a higher tendency of stent occlusion due to food reflux in metastatic gastric cancer patients with previous gastrectomy. The altered peristaltic movement after gastric operation also could contribute to food reflux and subsequent stent occlusion. Presently, however, we did not observe stent occlusion resulting from tumor ingrowth or stent migration. It is also difficult to compare relatively shorter median patient survival and stent patency time of this study with results of previous studies, as most of the study patients had late stage of disease.

The present study has several limitations. First, this stent
system is not yet commercially available outside of Korea. Second, median survival was only 92 days, which limited the ability to observe stent patency over a longer period of time. The relatively short life expectancy is likely related to the severity of the patients’ underlying disease. Finally, because this study had no control group, further comparative studies with other existing covered stent may be needed.

In conclusion, percutaneous placement of a covered stent system with long duodenal extension is feasible and safe. However, this stent system may not completely prevent stent occlusion caused by food reflux.

REFERENCES

1. Gillams A, Dick R, Dooley JS, Wallsten H, el-Din A. Self-expandable stainless steel braided endoprosthesis for biliary strictures. *Radiology* 1990;174:137-140
2. Lammer J, Hausegger KA, Flückiger F, Winkelbauer FW, Wildring L, Klein GE, et al. Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents. *Radiology* 1996;201:167-172
3. Lee BH, Choe DH, Lee JH, Kim KH, Chinn SY. Metallic stents in malignant biliary obstruction: prospective long-term clinical results. *AJR Am J Roentgenol* 1997;168:741-745
4. Ho CS, Warkentin AE. Evidence-based decompression in malignant biliary obstruction. *Korean J Radiol* 2012;13:556-561
5. Thurnher SA, Lammer J, Thurnher MM, Winkelbauer F, Graf O, Wildring R. Covered self-expanding transhepatic biliary stents: clinical pilot study. *Cardiovasc Intervent Radiol* 1996;19:10-14
6. Hausegger KA, Thurnher S, Bodendorfer G, Zollkofer CL, Ugovitmerz K, Kugler C, et al. Treatment of malignant biliary obstruction with polyurethane-covered Wallstents. *AJR Am J Roentgenol* 1998;170:403-408
7. Rossi P, Bezzi M, Salvatori FM, Panzetti C, Rossi M, Pavia G. Clinical experience with covered wallstents for biliary malignancies: 23-month follow-Up. *Cardiovasc Intervent Radiol* 1997;20:441-447
8. Kanasaki S, Furukawa A, Kane T, Murata K. Polyurethane-covered Nitinol Strecker stents as primary palliative treatment of malignant biliary obstruction. *Cardiovasc Intervent Radiol* 2000;23:114-120
9. Schoder M, Rossi P, Uflacker R, Bezzi M, stadler A, Funovics MA, et al. Malignant biliary obstruction: treatment with ePTFE-FEP-covered endoprostheses initial technical and clinical experiences in a multicenter trial. *Radiology* 2002;225:35-42
10. Bezzi M, Zolovkins A, Cantisani V, Salvatori FM, Rossi M, Fanelli F, et al. New ePTFE/FEP-covered stent in the palliative treatment of malignant biliary obstruction. *J Vasc Interv Radiol* 2002;13:581-589
11. Hatzidakis A, Kroklidis M, Kalbakis K, Romanos J, Petrakis I, Gourtsoyiannis N. ePTFE/FEP-covered metallic stents for palliation of malignant biliary disease: can tumor ingrowth be prevented? *Cardiovasc Intervent Radiol* 2007;30:950-958
12. Han YM, Kwak HS, Jin GY, Lee SO, Chung GH. Treatment of malignant biliary obstruction with a PTFE-covered self-expandable nitinol stent. *Korean J Radiol* 2007;8:410-417
13. Fanelli F, Orsaga G, Bezzi M, Rossi P, Allegretti M, Passariello R. Management of malignant biliary obstruction: technical and clinical results using an expanded polytetrafluoroethylene fluorinated ethylene propylene (ePTFE/FEP)-covered metallic stent after 6-year experience. *Eur Radiol* 2008;18:911-919
14. Gwon DJ, Ko GY, Kim JH, Yoon HK, Lee JS, Kim KA, et al. A comparative analysis of PTFE-covered and uncovered stents for palliative treatment of malignant extrahepatic biliary obstruction. *AJR Am J Roentgenol* 2010;195:W463-W469
15. Kim JW, Gwon D, Han YM, Won JH, Hong HP, Ko GY, et al. A prospective, multicenter study of a double stent system for palliative treatment of malignant extrahepatic biliary obstructions. *Acta Radiol* 2015;56:1209-1215
16. Guaglianone E, Cardines R, Vuotto C, Di Rosa R, Babini V, Mastrantonio P, et al. Microbial biofilms associated with biliary stent clogging. *FEMS Immunol Med Microbiol* 2010;59:410-420
17. Leung JW, Ling TK, Kung JL, Vallance-Owen J. The role of bacteria in the blockage of biliary stents. *Gastrointest Endosc* 1988;34:19-22
18. van Berkel AM, van Marle J, Groen AK, Bruno MJ. Mechanisms of biliary stent clogging: confocal laser scanning and scanning electron microscopy. *Endoscopy* 2005;37:729-734
19. Hu B, Wang TT, Shi ZM, Wang SZ, Lu R, Pan YM, et al. A novel antireflux metal stent for the palliation of biliary malignancies: a pilot feasibility study (with video). *Gastrointest Endosc* 2011;73:143-148
20. Kim DU, Kwon CI, Kang DH, Ko KH, Hong SP. New antireflux self-expandable metal stent for malignant lower biliary obstruction: in vitro and in vivo preliminary study. *Dig Endosc* 2013;25:60-66
21. Hamada T, Isayama H, Nakai Y, Kogure H, Togawa O, Kawakubo K, et al. Novel antireflux covered metal stent for recurrent occlusion of biliary metal stents: a pilot study. *Dig Endosc* 2014;26:264-269
22. Hu B, Wang TT, Wu J, Shi ZM, Gao DJ, Pan YM. Antireflux stents to reduce the risk of cholangitis in patients with malignant biliary strictures: a randomized trial. *Endoscopy* 2014;46:120-126
23. Lee YN, Moon JH, Choi HJ, Choi MH, Lee TH, Cha SW, et al. Effectiveness of a newly designed antireflux valve metal stent to reduce duodenobiliary reflux in patients with unresectable distal malignant biliary obstruction: a randomized, controlled pilot study (with videos). *Gastrointest Endosc* 2016;83:404-412
24. Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of interventional radiology clinical practice guidelines. *J Vasc Interv Radiol* 2003;14:S199-S202
25. Misra SP, Dwivedi M. Reflux of duodenal contents and cholangitis in patients undergoing self-expanding metal stent placement. *Gastrointest Endosc* 2009;70:317-321